Report Overview

Germanys Psoriasis market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX.X% during the forecast period.

The German Annual National Conference on Health Care in Psoriasis established in 2009 consented to National Health Care Goals in Psoriasis 20102015 and defined a set of quality indicators, which are monitored on a regular basis. Between 2005 and 2014, 7 out of 8 quality indicators have markedly improved, and regional disparities were resolved. This remarkable foot owes to the research and developments made by German major players.



Market Drivers

The growth of the Psoriasis market is majorly driven by factors such as increasing public awareness, approval of new drugs, and boost in psoriasis Research and Development investment. The rise in psoriasis patients in the past few years can also be attributed to climate change, stress, and unhealthy lifestyle.

Furthermore, Psoriasis networks have been founded to substantially improve the quality of care for patients suffering from psoriasis in Germany. The strategy is to join forces of those dermatologists and departments with high expertise in the treatment of psoriasis and psoriatic arthritis, and that regard themselves as top-level providers for this disease. The networks have associations with office dermatologists that support the networks by referring difficult patients to the network. The key restraints of the market are the high cost involved in drug development, patent expiry of brand name drugs, side effects from the systemic and biologics medication, and health insurance issue.